<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02890134</url>
  </required_header>
  <id_info>
    <org_study_id>PRECISESADS INCP (RB 15.007)</org_study_id>
    <nct_id>NCT02890134</nct_id>
  </id_info>
  <brief_title>Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort</brief_title>
  <acronym>PRECISESADSI</acronym>
  <official_title>Molecular Reclassification to Find Clinically Useful Biomarkers for Systemic Autoimmune Diseases: Inception Cohort</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Pública Andaluza Progreso y Salud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Biopharma S.P.R.L.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Atrys Health, SA.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agencia Estatal Consejo Superior de Investigaciones Científicas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Servicio Cántabro de Salud</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>August Pi Sunyer Biomedical Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinikum der Universität Köln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hannover Medical School</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medizinische Universitat Wien</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Quartz Bio S.A.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Andaluz Health Service</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Cyprus Foundation for Muscular Dystrophy Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad de Granada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Milan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Geneva, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Szeged University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Recherches Internationales Servier</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi-Aventis Research &amp; Développement</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro Hospitalar do Porto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Investigación Biomédica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Innovative Medicines Initiative</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Connective tissue diseases (CTD) or systemic autoimmune diseases (SADs) as they are known
      today are a group of chronic inflammatory conditions with autoimmune aetiology with few
      treatment options and difficult diagnosis.Brest team contribute to performe a new
      classification of the following systemic autoimmune diseases in a European Union's Seventh
      Framework Programme. The aim of this research consiteis to reclassify the individuals
      affected by SADs into molecular clusters instead of clinical entities through the
      determination of molecular profiles using several &quot;Omics&quot; techniques.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The overall objective of the PRECISESADS IMI project is to reclassify the individuals
      affected by SADs into clusters of molecular, instead of clinical entities through the
      determination of molecular profiles using several &quot;-omics&quot; techniques.

      The identification of the clusters relies on a cross sectional (CS) cohort/protocol where
      2666 individuals (2000 patients and 666 controls) including a sub-study of 288 deeply
      characterized individuals (240 patients and 48 controls) are to be recruited.

      In parallel a longitudinal inception cohort/protocol will be started in order to further
      explore the clinical relevance of the identified clusters and their evolution over time.

      The objectives of the CS study and sub-study are:

        1. To identify a systemic taxonomy for patients with SADs by producing the following data
           in individuals with SADs and controls: genetic, epigenomic, transcriptomic, flow
           cytometric (from peripheral blood mononuclear cells (PBMCs)), metabolomics and proteomic
           in plasma and urine, exosome analysis, classical serology (antibodies and
           autoantibodies), and clinical data.

        2. To better characterize individual SADs at the omics level.

        3. To perform clustering analyses to determine the groups of individuals who,
           differentially from other groups, share specific molecular features (precision
           medicine).

        4. A deeper analysis will be done in a substudy of 288 individuals.

      The clustering process will be data-driven with the aim to find the most homogenous and
      differentiated clusters of diseases that clearly separate differentiate individuals from
      controls and other patient clusters.

      Aims of the Inception cohort:

      Specifically, this inception cohort aims at:

        1. assign individuals newly diagnosed with an systemic autoimmune disease (SAD) to any of
           the reclassification clusters discovered in the CS study,

        2. to study the development and modifications of OMICS signatures/clusters occurring in
           each individual patient in the course of the disease, including the impact of treatment
           on their individual pattern, and

        3. to perform deep (thorough) OMICs studies to compare their patterns of OMICS as a group,
           with the patterns obtained in the CS cohort.

      The inception cohort will have patient follow up and sample collection at baseline, month
      6(±1 month) and month 18 (±1 month).

      As the newly diagnosed patients we plan to recruit will have minimum or no treatment, we will
      identify differences and similitudes to patients from the cross-sectional study that have
      undergone long-term treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Gene expression in total blood</measure>
    <time_frame>2 years</time_frame>
    <description>Gene expression will be done using commercial gene expression microarrays in total blood from all samples using the RNA Paxgene tube.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow cytometry analysis to determine cell proportions in the total blood mixture in all individuals.</measure>
    <time_frame>24 hours</time_frame>
    <description>9 optimized panels of antibodies will be used to determine cell subpopulations in peripheral blood (including very minor cell populations).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genotyping</measure>
    <time_frame>2 years</time_frame>
    <description>Genotyping will be done using a whole genome array.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Metabolite determination</measure>
    <time_frame>2 years</time_frame>
    <description>Metabolite determination in plasma and urine using Nuclear Magnetic Resonance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Exosome isolation from plasma and urine</measure>
    <time_frame>2 years</time_frame>
    <description>set up of the methodology for isolating exosomes in these bodily fluids for gene expression analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cytokine profile determination</measure>
    <time_frame>2 years</time_frame>
    <description>88 different cytokines will be assessed with Luminex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>routine autoantibodies in serum</measure>
    <time_frame>2 years</time_frame>
    <description>set of serum autoantibodies will be determined in a European validated laboratory. Also, they will perform detection of antibodies against small lipid moieties i.e.antiphosphorylcholine),lupus anticoagulant and complement proteins in plasma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gene methylation in total blood</measure>
    <time_frame>2 years</time_frame>
    <description>Methylation analysis will be done using the methylome 450k array using the DNA obtained from total blood. MicroRNA gene expression arrays using total blood.</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Systemic Autoimmune Diseases</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with systemic autoimmune diseases
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  · Aged 18 years or older at the time of consent

               -  Diagnosed according to prevailing criteria for one of the following systemic
                  autoimmune diseases (see Annex 2)

                    -  Rheumatoid arthritis (RA)

                    -  Scleroderma or systemic sclerosis (SSc)

                    -  Primary Sjögren's syndrome (SjS)

                    -  Systemic lupus erythematosus (SLE)

                    -  Primary antiphospholipid syndrome (PAPS)

                    -  Mixed Connective Tissue Disease (MCTD)

                    -  Patients with undifferentiated connective tissue disease (UCTD) for over 1
                       year and that do not fulfill the diagnosis of any of the above diseases.

               -  Signed the informed consent form

        Exclusion Criteria:

          -  · Patients unable to understand the procedures related to the protocol should not be
             included. The study is voluntary and patients must be able to give their informed
             consent.

               -  Pregnant women

               -  Neonatal lupus

               -  Drug-induced lupus

               -  Patients whose condition is so serious that they cannot take part in the study

               -  Severe nephrotic syndrome with proteinuria &gt;=3,5 g/day

               -  Patients with stable doses of steroids &gt;15mg/day for the last 3 months or with IV
                  corticosteroids in the last 3 months

               -  Patients under immunosuppressants for the last 3 months prior to recruitment
                  with:

                    -  Methotrexate ≥25mg/week

                    -  Azathioprine ≥2.5mg/kg/day

                    -  Cyclosporine A &gt; 3mg/kg/day

                    -  Mycophenolate Mofetil &gt; 2gr/day

               -  Treatment with cyclophosphamide (any dose or route of administration) or
                  Belimumab in the past 6 months

               -  Patients with combined therapy of two or more immunosuppressants

               -  Patients on depletative therapy such as Rituximab in the last year

               -  Patients receiving experimental

               -  Overlap syndromes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marta Alarcon</last_name>
    <role>Study Director</role>
    <affiliation>Fundación Pública Andaluza Progreso y Salud (PHFSpain)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marta Alarcon</last_name>
    <email>marta.alarcon@genyo.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jacques-Olivier Pers</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Université catholique de Louvain - Cliniques Universitaires Saint-Luc (UCL)</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Lauwerys</last_name>
      <email>bernard.lauwerys@uclouvain.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - KU Leuven, Department of Rheumatology (KU LEUVEN)</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rik Lories</last_name>
      <email>rik.lories@kuleuven.be</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Brest</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain SARAUX</last_name>
      <email>alain.saraux@chu-brest.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Falk Hiepe</last_name>
      <email>falk.hiepe@charite.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico (IRCCS)</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorenzo Beretta</last_name>
      <email>lorberimm@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic I Provicia- Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ricard Cervera</last_name>
      <email>rcervera@clinic.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía Andaluz de Salud</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eduardo Collantes</last_name>
      <email>educollantes@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario San Cecilio Servicio Andaluz de Salud</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Norberto Ortego</last_name>
      <email>norberto@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de las Nieves Granada</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Raya</last_name>
      <email>enriraya@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospitaux Universitaires de Géneve (UNIGE)</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Chizzolini</last_name>
      <email>Carlo.Chizzolini@unige.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2016</study_first_submitted>
  <study_first_submitted_qc>August 31, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2016</study_first_posted>
  <last_update_submitted>December 9, 2016</last_update_submitted>
  <last_update_submitted_qc>December 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SADs</keyword>
  <keyword>Molecular Reclassification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

